Gilead tags Merck for first-line triple negative breast cancer trial
pharmaphorum
OCTOBER 29, 2021
The company also reported strong gains for its lymphoma cell therapy products Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel), collectively up 51% to $222 million. The post Gilead tags Merck for first-line triple negative breast cancer trial appeared first on. billion for the full year.
52 
Let's personalize your content